Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Gastrointestinal 1CNS 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 36Capecitabine 28Trastuzumab 23Paclitaxel 22Surveys and Questionnaires 20Cyclophosphamide 20Gemcitabine 18Docetaxel 18Carboplatin 15Nivolumab 14Methods 14Magnetic Resonance Spectroscopy 13Early Intervention, Educational 13Bevacizumab 13Interviews as Topic 12Blood Specimen Collection 12fludarabine 11Standard of Care 11Irinotecan 11olaparib 10durvalumab 10Specimen Handling 10Psychiatric Rehabilitation 10palbociclib 9aldesleukin 9Taxes 9Fulvestrant 9Fluorouracil 9Exercise 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Immunoconjugates × Gastrointestinal × Clear all
NCT03255070 2024-02-01

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Ambrx, Inc.

Phase 1 Completed
106 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡